Penserra Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Penserra Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33K	Buy	+594	New	+$32.5K	﹤0.01%	835
2024 Q4	–	Sell	-9	Closed	–	–	1112
2024 Q3	$0	Sell	9 -3	-25%	-$251	﹤0.01%	1120
2024 Q2	$1K	Sell	12 -3	-20%	-$250	﹤0.01%	1210
2024 Q1	$1K	Hold	15	–	–	﹤0.01%	1179
2023 Q4	$1K	Hold	15	–	–	﹤0.01%	1223
2023 Q3	$1K	Buy	15 +5	+50%	+$445	﹤0.01%	1212
2023 Q2	$0	Hold	10	–	–	﹤0.01%	1267
2023 Q1	$0	Hold	10	–	–	﹤0.01%	1125
2022 Q4	$1K	Buy	+10	New	+$939	﹤0.01%	1079
2020 Q2	–	Sell	-1,115	Closed	-$106K	–	812
2020 Q1	$106K	Buy	+1,115	New	+$96.1K	0.01%	553
2019 Q3	–	Sell	-1,596	Closed	-$136K	–	859
2019 Q2	$136K	Buy	+1,596	New	+$137K	0.01%	443
2017 Q1	–	Sell	-224	Closed	-$18K	–	588
2016 Q4	$18K	Buy	224 +39	+21%	+$3.35K	﹤0.01%	680
2016 Q3	$17K	Buy	185 +74	+67%	+$6.97K	﹤0.01%	602
2016 Q2	$9K	Buy	111 +41	+59%	+$3.49K	﹤0.01%	719
2016 Q1	$5K	Buy	70 +2	+3%	+$163	﹤0.01%	828
2015 Q4	$7K	Buy	+68	New	+$7.1K	﹤0.01%	602

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Penserra Capital Management's BMRN Position: Q2 2026 in Review

Penserra Capital Management opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 594 shares worth $33K. The stake represents ﹤0.01% of the portfolio and ranks #835 among its holdings. This is a return to the name: Penserra Capital Management previously reported a position in BMRN as recently as Q3 2024.

Penserra Capital Management first reported a position in BMRN in Q4 2015 and has held it in 16 quarters since. The position peaked at $136K in Q2 2019. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Penserra Capital Management held 594 shares of BioMarin Pharmaceuticals worth $33K as of Q2 2026.
BioMarin Pharmaceuticals was a new Penserra Capital Management position in Q2 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of Penserra Capital Management's portfolio in Q2 2026, its #835 holding.
Penserra Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2015 and has held it in 16 quarters since.
Penserra Capital Management's BioMarin Pharmaceuticals position peaked at $136K in Q2 2019.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Penserra Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.